SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ccryder who wrote (776)5/15/2000 10:32:00 AM
From: opalapril  Read Replies (1) of 834
 
Texas Biotechnology Announces First Quarter Financial Results and Updates Shareholders on Key Corporate Programs

Net Loss Increases Due to Initiation of Phase II Pulmonary Hypertension Clinical Trial for Sitaxsentan and Pre-Marketing Programs for NOVASTAN(R) (Argatroban)

Submits Complete Response to the U.S. FDA Approvable Letter for NOVASTAN

* * *
"TBC announced that it has submitted its response to the approvable letter for NOVASTAN issued by the U.S. Food & Drug Administration on February 18, 2000. The approvable letter from FDA included the Agency's recommendation for NOVASTAN as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). Based on recent discussions with representatives from FDA, TBC expects a response from the Agency by mid July."

biz.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News